OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data
<p>Trigeminal neuralgia (TN) patients may develop side effects from centrally acting drugs, have contraindications for neurosurgical procedures, or experience relapse during conventional therapies. OnabotulinumtoxinA (BoNT/A) has been reported to be effective for TN, although this finding has...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações
2015-01-01
|
| Series: | Arquivos de Neuro-Psiquiatria |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2015005050109&lng=en&tlng=en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850237530545324032 |
|---|---|
| author | Pedro A. Kowacs Marco A. T. Utiumi Fábio A. Nascimento Elcio J. Piovesan Helio A. G. Teive |
| author_facet | Pedro A. Kowacs Marco A. T. Utiumi Fábio A. Nascimento Elcio J. Piovesan Helio A. G. Teive |
| author_sort | Pedro A. Kowacs |
| collection | DOAJ |
| description | <p>Trigeminal neuralgia (TN) patients may develop side effects from centrally acting drugs, have contraindications for neurosurgical procedures, or experience relapse during conventional therapies. OnabotulinumtoxinA (BoNT/A) has been reported to be effective for TN, although this finding has been challenged. An overview of the available evidence based on a narrative/qualitative analysis of the literature is presented. About 90% of patients who receive BoNT/A show an improvement, a higher figure than that reported for the placebo effect of BoNT/A for other headaches. Tolerability of BoNT/A is good, and its few side-effects are transient. The articles reviewed were mainly case reports, case series and open-label trials; however, randomized controlled trials have endorsed the efficacy of BoNT/A for TN. This evidence, together with a better understanding of the analgesic mechanisms of BoNT/A and its proven efficacy in treating other pain syndromes, supports the use of this toxin as a therapeutic option for TN.</p> |
| format | Article |
| id | doaj-art-2ac08eae30c24e3f870c4f31dbde7cef |
| institution | OA Journals |
| issn | 1678-4227 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Thieme Revinter Publicações |
| record_format | Article |
| series | Arquivos de Neuro-Psiquiatria |
| spelling | doaj-art-2ac08eae30c24e3f870c4f31dbde7cef2025-08-20T02:01:42ZengThieme Revinter PublicaçõesArquivos de Neuro-Psiquiatria1678-42272015-01-010000010.1590/0004-282X20150109S0004-282X2015005050109OnabotulinumtoxinA for trigeminal neuralgia: a review of the available dataPedro A. KowacsMarco A. T. UtiumiFábio A. NascimentoElcio J. PiovesanHelio A. G. Teive<p>Trigeminal neuralgia (TN) patients may develop side effects from centrally acting drugs, have contraindications for neurosurgical procedures, or experience relapse during conventional therapies. OnabotulinumtoxinA (BoNT/A) has been reported to be effective for TN, although this finding has been challenged. An overview of the available evidence based on a narrative/qualitative analysis of the literature is presented. About 90% of patients who receive BoNT/A show an improvement, a higher figure than that reported for the placebo effect of BoNT/A for other headaches. Tolerability of BoNT/A is good, and its few side-effects are transient. The articles reviewed were mainly case reports, case series and open-label trials; however, randomized controlled trials have endorsed the efficacy of BoNT/A for TN. This evidence, together with a better understanding of the analgesic mechanisms of BoNT/A and its proven efficacy in treating other pain syndromes, supports the use of this toxin as a therapeutic option for TN.</p>http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2015005050109&lng=en&tlng=enneuralgia do trigêmeoneurotoxina botulínica do tipo Atoxina botulínica do tipo Atoxina onabotulinica Ador neuropática |
| spellingShingle | Pedro A. Kowacs Marco A. T. Utiumi Fábio A. Nascimento Elcio J. Piovesan Helio A. G. Teive OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data Arquivos de Neuro-Psiquiatria neuralgia do trigêmeo neurotoxina botulínica do tipo A toxina botulínica do tipo A toxina onabotulinica A dor neuropática |
| title | OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data |
| title_full | OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data |
| title_fullStr | OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data |
| title_full_unstemmed | OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data |
| title_short | OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data |
| title_sort | onabotulinumtoxina for trigeminal neuralgia a review of the available data |
| topic | neuralgia do trigêmeo neurotoxina botulínica do tipo A toxina botulínica do tipo A toxina onabotulinica A dor neuropática |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2015005050109&lng=en&tlng=en |
| work_keys_str_mv | AT pedroakowacs onabotulinumtoxinafortrigeminalneuralgiaareviewoftheavailabledata AT marcoatutiumi onabotulinumtoxinafortrigeminalneuralgiaareviewoftheavailabledata AT fabioanascimento onabotulinumtoxinafortrigeminalneuralgiaareviewoftheavailabledata AT elciojpiovesan onabotulinumtoxinafortrigeminalneuralgiaareviewoftheavailabledata AT helioagteive onabotulinumtoxinafortrigeminalneuralgiaareviewoftheavailabledata |